Fig 1.
A: PRDX3 expression in human organs. B: Sub-cellular localization of PRDX3. C: First-neighbor network including 119 nodes. D: Expression profile of PRDX3 between tumor and normal samples. E: PRDX3 mRNA expression and gene alteration. F: PRDX3 alteration frequency in different cancers.
Fig 2.
PRDX3 and clinical prognosis in cancers.
A: Summary of correlations of PRDX3 with clinical prognosis using Kaplan-Meier and cox regressions (OS: overall survival; PFI: progression-free internal; DSS: disease specific survival; DFI: disease-free interval). The red R means risky, the blue P means protective, and the blank means no significance. B-E: Forest plot about the prognostic roles of PRDX3 in cancers: OS, PFI, DSS and DFI. The log 10 of hazard ratio (HR) is achieved. The red means the HR is > 1, and the green means the HR is < 1. There are no significances for these lines including zero.
Fig 3.
PRDX3 and pathways in cancers.
A: Associations between PRDX3 and signaling pathways in cancers. B: PRDX3 and cell death relevant pathways in cancers. The colors of circles represent correlation, and the size of circle means -log10(FDR). The bigger the circle is, the smaller P value is. FDR: false discovery rates, and all P values were corrected using FDR. The while circle means no significance.
Fig 4.
PRDX3 and tumor microenvironment in cancers.
A: PRDX3 and TMB in cancers. The dots mean the correlations between PRDX3 expression and TMB in different cancers. The value>0 means positive correlation, and value<0 means negative correlation. *: P < 0.05; **: P < 0.01; ***: P < 0.001; **** = P < 0.0001. B: PRDX3 and MSI in cancers. The value>0 means positive correlation, and value<0 means negative correlation. *: P < 0.05; **: P < 0.01; ***: P < 0.001; **** = P < 0.0001. C-R: correlations of PRDX3 expression with immune scores in BLCA, BRCA, CESC, CHOL, KIRC, KIRP, LGG, LIHC, LUAD, PRAD, SARC, TGCT, THCA, UCES, UCEC, GBM, and LUSC. The x-axis = immune score in cancers, and the y-axis = PRDX3 expression cancers.
Fig 5.
Associations between PRDX3 and immune infiltration levels in cancers.
The colors of square means p values, the red is positive correlated, the blue is negative correlated, and the x square means no significance.
Fig 6.
Associations between PRDX3 and immune regulators in cancers.
A: PRDX3 and immune activated genes. B: PRDX3 and immune inhibited genes. *: P < 0.05; **: P < 0.01; ***: P < 0.001; **** = P < 0.0001.
Fig 7.
Associations between PRDX3 and chemokine regulators.
A: PRDX3 and chemokine genes. B: PRDX3 and chemokine receptor genes. *: P < 0.05; **: P < 0.01; ***: P < 0.001; **** = P < 0.0001.
Fig 8.
PRDX3 independently predicted prognosis of KIRC patients.
A: low expression of PRDX3 in KIRC. B: ROC curve of PRDX3 in diagnosing KIRC. C: Immunohistochemistry of PRDX3 in KIRC and normal tissues. D: Association between PRDX3 and clinical stages. E and F: Univariate and multivariate cox regressions of PRDX3 in KIRC. G: Nomograph of PRDX3 predicting prognosis in KIRC. H: Calibration plot assessing the nomogram prediction model.
Fig 9.
PRDX3 over-expression inhibited tumor progression in KIRC cells.
A: Western blot showing PRDX3 over-expression in 786−0 and Caki-1 cells. B: qPCR showing elevated PRDX3 in KIRC cells. Data (n = 3) are shown as mean ± standard error (SE), * = P < 0.05; ** = P < 0.01; *** = P < 0.001; **** = P < 0.0001. C: PRDX3 over-expression inhibited wound healing. Data are shown as mean ± standard error (SE), * = P < 0.05; ** = P < 0.01; *** = P < 0.001; **** = P < 0.0001. D and E: PRDX3 over-expression inhibited migration and invasion in KIRC cells. Data are shown as mean ± standard error (SE), * = P < 0.05; ** = P < 0.01; *** = P < 0.001; **** = P < 0.0001.
Fig 10.
PRDX3 inhibited KIRC progression via regulating PPAR signaling pathway.
A: KEGG pathway enrichment of PRDX3. B: Scatter plot of correlation of PRDX3 with PPARA. C and D: Western blot and qPCR showing high PPARA expression in PRDX3 over-expressing cells. The qPCR was shown using (n = 3) mean ± standard error (SE), * = P < 0.05; ** = P < 0.01; *** = P < 0.001; **** = P < 0.0001. E and F: PRDX3 promoting Bax, BMF, and Bim expressions and inhibiting CCND, CCL20 and MMP9 expressions. Data (n = 3) are shown as mean ± standard error (SE), * = P < 0.05; ** = P < 0.01; *** = P < 0.001; **** = P < 0.0001. G, H and I: wound healing, migration and invasion abilities suppressed after adding PPAR inhibitor. Data (n = 3) are shown as mean ± standard error (SE), * = P < 0.05; ** = P < 0.01; *** = P < 0.001; **** = P < 0.0001.